EAACI Digital Congress 2020
- Final Programme -
Bridging innovations into allergy and asthma prevention

Welcome to EAACI Digital Congress 2020!

Under the timely motto “Bridging innovations into Allergy and Asthma Prevention”, we are offering you the opportunity to explore our rich scientific programme in a truly innovative way. What better way to be updated on the conceptual and technological advances in our field, than by taking part in a brand-new technological approach to our EAACI Annual Congress?

During the Congress you will be able to:
- Tune in and watch a variety of virtual sessions in your own time and without missing out;
- Discuss important topics and ask your questions via an interactive Q&A;
- Consult our vast number of abstracts, posters and webcast symposia with novel research any time during the congress period;

In order to match this digital format, we have split our Scientific Programme in 3 parts:

Live Scientific Programme

A selection of the most exceptional sessions, to be delivered to you from June 6 to 8. You will find the details of this programme from pages 23 to 36.

Industry Programme

All the valuable content brought to you by our sponsors and exhibitors.

Recorded Scientific Programme

All the content originally included in the Scientific Programme prepared for the EAACI Congress 2020 in London:
- Symposia (SYM)
- Interactive Symposia (ISYM) and Workshops (IWS)
- Hot Topics (HT)
- Year in Review (YIR)
- Interactive Postgraduate Courses (IPGC)
- Pro & Cons (P&C)
- Ethics Sessions (ES)
- Sister Society Symposia (SSS)
- Late-Breaking Oral Abstract Sessions (LB OAS)
- Late-Breaking Poster Discussion Sessions (LB PDS)
- Late-Breaking Thematic Poster Sessions (LB TPS)
- Oral Abstract Sessions (OAS)
- Poster Discussion Sessions (PDS)
- Thematic Poster Sessions (TPS)

A selection of the content will be available for 6 months after the Congress.
Welcome messages

Bridging innovations into allergy and asthma prevention

It is my great pleasure to invite you to the first ever digital EAACI Annual Congress 2020, which will be held from 6 to 8 June.

In the next few years, medical innovations will fundamentally revolutionize the healthcare system, with the goal of improving peoples’ quality of life. This year’s Congress motto suggests that we will not only present state-of-the-art knowledge in allergy and clinical immunology but will go beyond this, bridging it with the most contemporary, inspiring and creative processes and ideas diffused and adapted to the needs of our patients.

Modern times also foster the revival of the old definition of innovation as a synonym for rebellion or revolt. Change is not only about embracing new ideas but also about leaving outdated ones behind, and what better opportunity to do so than taking part in this completely new format of Annual Congress?

Do not miss the chance to take part in the modern allergology paradigm shift driven by new discoveries: endotype and phenotype approaches that change not only the taxonomy but the way we perceive and manage the allergic disease. The interactive sessions and discussions designed to match the expectations of all participants will provide a platform to stimulate the creativity of thousands of delegates, and the high-throughput screening of viable solutions using the innovative digital format.

Join us at the EAACI Congress 2020!

Marek Jutel
EAACI President 2019-2021

---

See you all online for the EAACI Digital Annual Congress!

On behalf of the Local Organising Committee, it is with great pleasure to invite you to the EAACI Annual Congress 2020, which this year will take part digitally from 6-8 June.

Our world is ever-changing, and with the advent of new technologies in medicine: omics, big data, mHealth and the development of artificial intelligence among others, this congress will provide a unique opportunity to foster and discuss these avenues in our field. The future includes tackling allergic diseases and asthma at their root, and these discoveries will be powerful tools to work towards prevention in our field.

You will be able to explore the same quantity and quality of scientific content that you would have experienced during our traditional Congress in London - while staying safe at home and benefiting financially.

Besides full access to the Digital Congress content, including Keynote symposia, state-of-the-art symposia, industry symposia, oral and poster presentations – you will also benefit from access to these resources for 6 months after the event.

We look forward to welcoming you to this new format of EAACI Congress where we will push boundaries with forward thinking and novel approaches to preventing allergy and asthma worldwide.

Mohamed Shamji
EAACI Digital Congress 2020 Chair

---

BECOME AN EAACI MEMBER

Over 12,000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.

Benefits applied to all categories

- Free subscription to online Allergy and PAI journals
- Full voting rights & eligibility for election
- Possibility to join Task Forces
- 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- EAACI Annual Congress Up to 25% discount
- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Subscription to printed journals (upon request)

* For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€

Junior Membership (under 36 years old)

Free

- EAACI Annual Congress Up to 55% discount
- EAACI Focused Meetings Up to 70% discount
- EAACI Schools & Master Classes Up to 50% discount
- Eligibility for EAACI fellowships & Scholarships
- Eligibility for EAACI events
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

EAACI / NAS Dual Membership

30€

- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership

Discover our full membership offer at EAACI.org/membership or send an email to member@eaaci.org

BECOME AN EAACI MEMBER

Over 12,000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.

Benefits applied to all categories

- Free subscription to online Allergy and PAI journals
- Full voting rights & eligibility for election
- Possibility to join Task Forces
- 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- EAACI Annual Congress Up to 25% discount
- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Subscription to printed journals (upon request)

* For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€

Junior Membership (under 36 years old)

Free

- EAACI Annual Congress Up to 55% discount
- EAACI Focused Meetings Up to 70% discount
- EAACI Schools & Master Classes Up to 50% discount
- Eligibility for EAACI fellowships & Scholarships
- Eligibility for EAACI events
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

EAACI / NAS Dual Membership

30€

- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership

Discover our full membership offer at EAACI.org/membership or send an email to member@eaaci.org

Over 12,000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.

Benefits applied to all categories

- Free subscription to online Allergy and PAI journals
- Full voting rights & eligibility for election
- Possibility to join Task Forces
- 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- EAACI Annual Congress Up to 25% discount
- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Subscription to printed journals (upon request)

* For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€

Junior Membership (under 36 years old)

Free

- EAACI Annual Congress Up to 55% discount
- EAACI Focused Meetings Up to 70% discount
- EAACI Schools & Master Classes Up to 50% discount
- Eligibility for EAACI fellowships & Scholarships
- Eligibility for EAACI events
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

EAACI / NAS Dual Membership

30€

- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership

Discover our full membership offer at EAACI.org/membership or send an email to member@eaaci.org

Over 12,000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.

Benefits applied to all categories

- Free subscription to online Allergy and PAI journals
- Full voting rights & eligibility for election
- Possibility to join Task Forces
- 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- EAACI Annual Congress Up to 25% discount
- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Subscription to printed journals (upon request)

* For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€

Junior Membership (under 36 years old)

Free

- EAACI Annual Congress Up to 55% discount
- EAACI Focused Meetings Up to 70% discount
- EAACI Schools & Master Classes Up to 50% discount
- Eligibility for EAACI fellowships & Scholarships
- Eligibility for EAACI events
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

EAACI / NAS Dual Membership

30€

- EAACI Focused Meetings 25% discount
- EAACI Schools & Master Classes Up to 40% discount
- Printed subscriptions for Allergy & PAI is an additional 60€ per year

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership

Discover our full membership offer at EAACI.org/membership or send an email to member@eaaci.org
EAACI Committees

EAACI Board of Officers
Marek Jutel, President
Jürgen Schwarze, Secretary General
Liam O'Mahony, Treasurer
Edward Knol, Vice-President Congresses
Stefano del Giacco, Vice-President Education & Specialty
Karín Hoffmann-Sommergruber, Vice-President Communications & Membership
Tomás Chivato, Vice-President Science
Ioana Agache, Past President

EAACI Section Chairpersons
Matteo Bonini, Asthma Section
Charlotte Mortz, Dermatology Section
Ludger Klimek, ENT Section
Eva Untersmyr-Elsenhuber, Basic & Clinical Immunology Section
Helen Brough, Pediatrics Section
Carmen Riggioni, Junior Members Section
Radoslaw Gawlik, Allied Health and Primary Care Section

EAACI Interest and Working Group Representatives
Jolanta Wakusiał-Skorupa
Oscar Palomares

Members at Large
Oliver Pfarr
Maria Torres
Isabel Skytala
Antti Lauerman
Markus Ollert
Asil Gelinick

Local Organising Committee (LOC)
Mohamed Shamji, EAACI Digital Congress 2020 Chair
Helen Brough, EAACI Digital Congress 2020 Co-Chair
Liam O'Mahony, EAACI Digital Congress 2020 Co-Chair
Shuaib Nasser, EAACI Digital Congress 2020 Co-Chair
Stephen Durham
Adam Fox
Clive Grattan
Isabel Skytala
Adrian Custovic
Fan Chunq
Rebecca Knibb
Jonathan Hourihane
Shelley Dua
Hassan Arshad
Ian Adcock
George da Toit
Nicola Brathwlate
Glenis Scadding
Madison Lenormand
Roisin Fitzsimons
Paul Turner
Tabi Leslie
Sebastian Johnston
Clare Lloyd
Paul Lavender
Catherine Hawrylowicz

Scientific Programme Committee (SPC)

Scientific Programme Committee 2020
Mohamed Shamji, Scientific Programme Committee Chair 2018-2020
Mohamed Shamji, EAACI Congress 2020 Chair
Marek Jutel, EAACI President 2019-2021
Ioana Agache, EAACI Past President 2017-2019
Jürgen Schwarze, EAACI Secretary General 2019-2021
Edward Knol, EAACI VP Congresses 2019-2021
Carsten Schmidt-Weber, EAACI VP Congresses 2017-2019
Tomas Chivato, EAACI VP Science 2019-2021
Helen Brough, EAACI Congress 2020 Co-Chair
Nasser Shuaib, EAACI Congress 2020 Co-Chair
Liam O'Mahony, EAACI Congress 2020 Co-Chair
Luis Delgado, EAACI Congress 2019 Chair

Section Secretaries 2019 – 2021
Milena Sokolowska, Basic & Clinical Immunology
Ibn Equiluz-Gracia, Asthma
Stefania Arasi, Pediatrics
Barbara Ballmer-Weber, Dermatology
Sanna Toppila-Salmi, ENT
Pasquale Combi, JM Assembly
Rissan Meyer, Allied Health & Primary Care

Section Secretaries 2017 – 2019
Isabella Quinti, Immunodeficiencies
Hermelijn Smits, Infections
Maria Torres, Environmental & Occupational Allergy
Hanneke Oude Elberink, Insect Venom Hypersensitivity
Jon Genuit, Epidemiology
Michelle Vaahtokari, Aerobiology & Air Pollution
Monika Raulf, Insect Venom Hypersensitivity
Jon Genuit, Comparative Veterinary Allergy
Audrey Dunn Galvin, Allied Health
Elizabeth Angier, Primary Care

Interest Group Chairs 2017 – 2019
Margitta Worm, Food Allergy
Marina Atanaskovic-Markovic, Drug Allergy
Lars, Jacobsen, Allergen Immunotherapy
Monika Raulf, Environmental and Occupational Allergy
Paolo Matricardi, Allergy Diagnosis & Systems Medicine
Elizabeth Angier, Allied Health & Primary Care

Working Group Chairs 2019 – 2021
Anna Sediva, Immunodeficiencies
Wojciech Falewko, Infections
Thomas Eiwegger, Biologicals
Maia Rahhal, Allergy, Asthma & Sport
Baru Bodur, Ocular Allergy
Antonella Cianferoni, Eosinophilic Esophagitis
Gunter Sturm, Insect Venom Hypersensitivity
Grzegorz Brozek, Epidemiology
Carmen Galan, Aerobiology & Air Pollution
Maria Escribese, Genomics & Proteomics
Isabella Pali-Schöll, Comparative Veterinary Allergy
Audrey Dunn Galvin, Allied Health
Elizabeth Angier, Primary Care

Working Group Chairs 2017 – 2019
Isabella Quinti, Immunodeficiencies
Hermelijn Smits, Infections
Oscar Palomares Gracia, Biologicals
Mariana Couto, Asthma, Asthma & Sport
Jean-Luc Faquereau, Ocular Allergy
Ingrid Termeerhorst, Eosinophilic Esophagitis
Hanneke Oude Elberink, Insect Venom Hypersensitivity
Jon Genuit, Epidemiology
Michelle Vaahtokari, Aerobiology & Air Pollution
Comelis M. Van Drunen, Genomics & Proteomics
Jozef Janda, Comparative Veterinary Allergy
James Gardner, Allied Health
Radoslaw Gawlik, Primary Care
gret to inform you that there will be
Due to the change of format, we re
Congress Scholarship
the digital congress.
email aproximmately two weeks after
The Certificate of Attendance can be
more information.
Abstracts
All abstracts will be listed on the EAACI
website as of Saturday, 6 June 2020.
Presented abstract (except DCPD)
texts will be published on the EAACI
Media Library and in the official EAACI
Journal Allergy after the congress.
Certificate of Attendance
The Certificate of Attendance can be
downloaded after completing the det-
egates survey, which will be sent via
e-mail approximately two weeks after
the digital congress.
CME Credits
The EAACI Digital Congress 2020,
06-08/2020 has been accredited-
by the European Accreditation Coun-
cil for Continuing Medical Education
(EACCME®) with 22 European CME
credits (ECMEC®). Each medical spe-
cialist should claim only those hours
of credit that he/she actually spent in
the educational activity. Click here for
more information.
Congress Scholarship
Due to the change of format, we re-
gret to inform you that there will be
no Scholarships for the EAACI Digital
Congress 2020. Nevertheless, we are
pleased to make the Digital Congress
registration free of charge for Junior
Members.
Disclaimer
Participants are encouraged to pur-
chase an insurance to cover loss in-
curred in the event of cancellation.
EAACI cannot be held liable for any
hindrance or disruption of the EAACI
Digital Congress 2020 proceedings
arising from natural, political, social or
economic events or other unforeseen
incidents beyond its control (force
majeure). Registration of a participant
implies acceptance of this condition.
The materials presented at this con-
tinuing medical education activity are
made available for educational pur-
poses only.
EAACI Campus
Visit the EAACI Campus virtual booth
to learn more about EAACI’s activi-
ties such as membership, publica-
tions, EAACI Media Library and future
events is available under one roof.
The booth will be open throughout the en-
tire congress, and an online team will
be available for questions through the
live chat during the following opening
hours:
Saturday, 6 June, 09:00 – 17:30 CET
Sunday, 7 June, 09:00 – 17:30 CET
Monday, 8 June, 09:00 – 17:30 CET
Language
The official language of EAACI Digital
Congress 2020 is English.
Virtual Exhibition
Join us in meeting with key industry
experts, exchange knowledge on criti-
cal areas of development and research
in allergy and immunology. The digital
exhibition will be open according to
the main scientific programme timeta-
ble, subject to final adjustments.
Start of Virtual Exhibition:
6 June 2020 – 9:00 (CET)
End of Virtual Exhibition:
6 December 2020 – 17:30 (CET)
General Assembly
EAACI’s General Assembly will take
place remotely during the EAACI Dig-
ital Congress 2020 on Monday 08
June, 08:00-09:00 CET. The Gen-
eral Assembly is an opportunity to be
informed about current activities
and future plans, and to actively partici-
pate in the life of the Academy.
You will be able to access the General
Assembly on Monday 08 June 2020
at 08:00 CET by logging in with your
EAACI member number and password.
Please note that only members with
voting rights (in good standing) will
be able to vote. Please click here to
log into your membership profile and
settle any outstanding fees for your
2020 membership. Payment must
be done by Friday 05 June 2020 at
19:00 CET in order to gain access
to the voting platform on Monday 08
June 2020.
National Society Village
The National Society Village is open
throughout the entire Digital Congress
and features the virtual booths of our
NAS from all over Europe. At each
booth you will be able to visualise
brochures, watch videos, consult im-
portant national resources and much
more. You will also have the chance
to interact with respective members
of the NAS through an e-mail form.
We encourage you to visit this area
to learn more about your country’s
very own society dedicated to allergy,
asthma and immunology, or explore
developments in the field from other
countries!
Posterior Exhibition Information
• Thematic Poster Sessions (TPS):
TPS can be found in the e-poster sec-
tion of the Digital Congress, together
with a voice-over, and will be available
in the EAACI Media Library.
• Poster Discussion Sessions (PDS):
PDS can be found in the e-poster sec-
tion of the Digital Congress, together
with a voice-over, and will be available
in the EAACI Media Library.
• Digital Congress Poster Display
(DCPD): DCPD can be found in the
e-poster section during the Digital Congress.
Photography, film and audio for
event documentation and public reporting
By participating in the EAACI Digital
Congress 2020 the delegate under-
stands that recordings of the digital
content and the capture of images and
videos to be publicly shared are pro-
hibited.
Press contact details
EAACI Public Affairs Specialist:
Chiara Hartmann,
Office number: +41 44 205 55 34
Email: chiara.hartmann@eaaci.org
Registration
Registration fee for delegates includes
full access to the EAACI Digital Con-
gress 2020 content including plenary
talks, symposia, workshops, industry
symposia, oral and poster presenta-
tions during the Congress and for 6
months after the event.
Technical Information
The EAACI Digital Congress 2020
interface will be user-friendly and ful-
ly responsive, allowing delegates to
watch all sessions from their laptops/
desktops, iPad/tablets, and mobile
phones. However it is recommend to
use computers, to get the best expe-
rience including live chat during ses-
ions within the Live Scientific Pro-
gramme, an important feature that
boosts interaction between you, facul-
ty and your peers. In regards to a pref-
erable web browser, we suggest Goog-
le Chrome as the most compatible one.
in order to provide a well streamlined
support, we kindly ask you to send any
technical queries directly to following
email address: support@eaaci.org.

About EAACI
The European Academy of Allergy
and Clinical Immunology (EAACI) is a
non-profit organisation active in the
field of allergic and immunologic dis-
eases such as asthma, rhinitis, ecze-
a, occupational allergy, food and
drug allergy and anaphylaxis.
EAACI was founded in 1956 in Flor-
ence and has become the largest med-
ical association in Europe in the field
of allergy and clinical immunology. It
includes over 12’000 members from
120 countries, as well as over 75
National Allergy Societies.
Visit www.eaaci.org for more information.

General information
EAACI Newsletter
Eager to get the latest news on our
activities, events, and perspectives
from the EAACI Family?
Read our latest issue of the EAACI
Newsletter which features a glimpse
into the exciting programme of the
Digital Congress, COVID-19 viewpoints
from our doctors and researchers
on the frontline, and much more!

Edition May 2020 available on EAACI.org
Focused Meetings

**FAAM 2020 - Food Allergy and Anaphylaxis Meeting**
15-17 October 2020 / Manchester, United Kingdom
For the sixth consecutive time FAAM 2020 will be the leading event in the area of food allergy and anaphylaxis where internationally acclaimed speakers will share their knowledge. The meeting’s programme will bring you the most recent research, opinion and best practice in the field of food allergy and anaphylaxis in children and adults, delving into the molecular and cellular mechanisms of food allergy and anaphylaxis, practicalities of diagnosis and patient management and exciting new developments for prevention and treatment.

**EUROBAT 2020 - European Consortium on Application of Flow Cytometry in Allergy**
15 October 2020 / Manchester, United Kingdom
The sessions of EUROBAT will cover the current applications of BAT in food allergy, insect allergy, drug hypersensitivity, urticaria as well as future and new developments. Each session will have invited speakers and open presentations based on abstract submissions. The event will also involve an interactive roundtable discussion on the topic “Globalized exchange of experiences for BAT quality assurance” with all attendees and invited guests.

**ISAF 2020 - International Severe Asthma Forum**
22-24 October 2020 / Rome, Italy
ISAF is a cutting edge and evidence-based EAACI Focused Meeting with a scientific programme including a broad range of session formats and designed to facilitate interactive and stimulating discussions. Among key topics of the 2020 edition there will be precision medicine, electronic-health, big data, microbiome, pharmacogenomics, medical devices, breathomics and regulatory aspects. Special relevance will be also given to severe asthma in children and during pregnancy.

**DHM 2021 - Drug Hypersensitivity Meeting**
Spring 2021 / Verona, Italy
The EAACI Drug Hypersensitivity Meeting (DHM 2021) taking place in Spring 2021, in Verona, Italy, is an interdisciplinary meeting, bringing together researchers and physicians from different disciplines. It is the leading event of its kind, attracting up to 600 physicians and researchers from all over the world.

Allergy Schools & Master Classes

**SAM 2021 - Skin Allergy Meeting**
11 – 13 March 2021 / Copenhagen, Denmark
Held in collaboration with the European Society for Contact Dermatitis (ESCD), SAM 2021 will give up to date information for clinicians and cover basic, translational and clinical aspects on diseases such as atopic dermatitis, contact dermatitis, occupational eczema and more. To increase the learning experience, practical courses, interactive workshops and case reports with an important "teaching point" will be implemented in addition to keynote lectures given by experts from top-level international institutions.

**Allergy School on Anaphylaxis: Etiology Prevention and Management**
Autumn 2020 / Izmir, Turkey
Anaphylaxis with its life-threatening potential has always been one of the most important emergencies for all clinicians. Therefore, it is essential to review the information we have in order to keep up with the recent advances. In lectures and interactive workshops, the Allergy School will host discussions regarding the causes, initiators and co-factors of anaphylaxis, possible preventive measures and management of anaphylaxis.

**Master Class on Perioperative Hypersensitivity**
Spring 2021 / Verona, Italy
The Master Class on Perioperative Hypersensitivity will provide a contemporary understanding of the clinical presentation, common causes and diagnostic work-up of patients referred for the investigation of perioperative hypersensitivity. The event’s faculty will focus on the importance of collaboration between allergists/immunologists and anaesthesiologists and will include absolute experts in the field presenting the latest evidence and their own practical experiences.

Due to COVID-19, some of our event dates and formats might be subject to change. More 2021 events will be announced shortly.
Thousands of resources
now available on EAACI Media Library

Guidelines
Abstracts
Books
Posters
Papers

Newsletters

Webcasts

All EAACI Resources are only 1 click away
Ceremonies

Welcome Ceremony

At the kick-off our EAACI 2020 Digital Congress tune in to three top-level Opening Keynote lectures under the theme of “Solutions and Challenges in Modern Medicine”. Explore present-day findings in relation to the COVID-19 pandemic and our field, and listen to Sir Gregory Winter, Nobel Prize Winner for Biochemistry address the way forward for biologicals in modern medicine.

In addition to these stimulating sessions, get the virtual feel of an exciting congress to come through welcome talks by our EAACI President and EAACI Congress Chair, and find out who these year’s recipients of our prestigious EAACI Awards are.

Closing Ceremony

At the close of our first digital Congress, we already look forward to the next opportunity for our community to meet in Madrid for the EAACI Congress 2021. The closing ceremony will give you a glimpse into its preparations, theme and programme through addresses from our 2021 Local Organising Committee. In addition, our EAACI President and Congress Chair 2020 take this opportunity to thank all participants and look back to this Congress’ successes and highlights.

Fellowship Winners

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Fellowships</td>
<td></td>
</tr>
<tr>
<td>Mattia Giovannini</td>
<td>Italy</td>
</tr>
<tr>
<td>Christos Fokolordos</td>
<td>France</td>
</tr>
<tr>
<td>Huyen Thanh Thuc</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Carina Petricau</td>
<td>Germany</td>
</tr>
<tr>
<td>Johnson Nameirakpam</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Deniz Eyice Karabacak</td>
<td>Austria</td>
</tr>
<tr>
<td>Fatma Esra Gunaydin</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Research Fellowships</td>
<td></td>
</tr>
<tr>
<td>Gustavo Jorge Molina</td>
<td>Belgium</td>
</tr>
<tr>
<td>Kristin Boykova Boteva</td>
<td>Germany</td>
</tr>
<tr>
<td>Mario Lovric</td>
<td>Denmark</td>
</tr>
<tr>
<td>Sandip D Kamath</td>
<td>Austria</td>
</tr>
<tr>
<td>Medium-term Research Fellowships</td>
<td></td>
</tr>
<tr>
<td>Jialing Jiang</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Angelika Tschepppe</td>
<td>Belgium</td>
</tr>
<tr>
<td>Amri Manel</td>
<td>Denmark</td>
</tr>
<tr>
<td>Long-term Research Fellowships</td>
<td></td>
</tr>
<tr>
<td>Ruben Fernandez Santamaria</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Didem Sanver Akbas</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Carole Florence Guillet</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Karolina Dumycz</td>
<td>Germany</td>
</tr>
</tbody>
</table>

Bridging Innovations into Allergy and Asthma Prevention

#EAACI2020
Dr. Akdis graduated from the Medical faculty of Uludag University, Bursa-Turkey in 1985. She is working at the Swiss Institute of Allergy and Asthma Research (SIAF) since 1995 and received her PhD in Immunology. Dr. Akdis worked as a postdoctoral scientist and became a group leader at SIAF, where she has established her own research group in 2003. Dr. Akdis made her habilitation (Venia Legendi) at the Zurich University Medical Faculty on Experimental Immunology in 2005 and became a professor in 2015. She has published more than 231 Peer-reviewed articles, Sum of times cited: 18'580 and her h-index: 74 (90-Google scholar).

Her major research contributions are on mechanisms of allergen tolerance, high dose allergen exposure models in humans, mechanisms of allergen-specific immunotherapy, functions of T regulatory cells, NK regulatory cells and recently IL-10 producing human B regulatory cells. Demonstration of immunological effects of rhinoviruses on T and B cells and breaking of immune tolerance to allergens, Demonstration of an angiogenesis promoting novel B cell subset. She has received research grants and collaborative grants from the Swiss National Foundation, European Union and Sean Parker Seed Grant. She received numerous awards, including Ferdinand Wortman Prize, Professor Hans Storck Award, Sedat Simavi Medicine Award, International Distinguished Fellow Award of the American College of Allergy, Asthma & Immunology (ACAAI), 2018. She is a board member of the World Allergy Organization (WAO) and has taken active roles in the organization of several EAACI Davos, Immunology Winter Schools and all the World Immune Regulation Meetings (WIRM) since their initiation in 2007.

José María Olaguibel
EAACI Fellow for Clinical Research

Dr. Olaguibel is active in clinical allergy practice, teaching (Clinical Assistant Professor of Medicine, Universidad de Navarra), and clinical research (Navarrabionmed.es), with a special interest in respiratory allergy, including lung function and airway inflammation, asthma diagnosis, and immunotherapy with allergens. He has produced more than 100 original articles published in international scientific journals (H index 28). He is a member of the American Academy of Asthma, Allergy and Clinical Immunology, the European Academy of Allergy and Clinical Immunology and the Spanish Society of Allergy and Clinical Immunology (Past President). By now, he is the Editor in Chief of the Journal of Investigational Allergology and Clinical Immunology (FI: 3.8), and has been recently involved in the development of the Spanish guidelines for asthma diagnosis and management (GEMA 5.0).
Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2020 will be presented during the Opening Ceremony - Saturday, 6 June 2020 at 19:45 CET.

Daniel Bovet Award for Treatment and Prevention 2020 – George du Toit
George du Toit is Professor of Paediatric Allergy, Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Trust and Kings College London. George is active in clinic research currently focusing on the LEAP-Trio and EAT-On food allergy prevention studies, the SAT II diagnostic study, and oral and epicutaneous peanut desensitisation trials. George is lead clinician for the Children’s Drug Allergy service at Evelina London Children’s Hospital and past Chairperson of the European Academy of Allergy and Clinical Immunology (EAACI) Paediatric Section.

Clemens von Pirquet Award for Clinical Research 2020 - Santiago Quirce
Santiago Quirce is Head of the Allergy Department at La Paz University Hospital, Professor of Respiratory Medicine at Universidad Autónoma of Madrid, and Director of the Research group on Allergic diseases at La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. He graduated in Medicine from the University of Santander and obtained his Ph.D. degree at the University of Cantabria, Spain, and received the Distinguished Alumni Award from this University in 2014. He did his postgraduate training as Research Fellow at Vancouver General Hospital, Respiratory Division, University of British Columbia, Canada. Dr. Quirce has edited and authored numerous publications, including 12 books and over 400 peer-reviewed papers. He has been a member of the Executive Committee of EAACI as representative of the Interest Groups, and Secretary of the Spanish Society of Allergy and Clinical Immunology.

PhARF Award 2020 – Paul Turner
Dr Paul Turner is a Clinician Scientist and Honorary Consultant in Paediatric Allergy & Immunology at Imperial College London, and Clinical Associate Professor at the University of Sydney, Australia. His research focuses on the pathophysiology of severe allergic reactions to food, and how this impacts upon allergen risk management and the use of precautionary allergen labelling. He leads the food allergy desensitisation programme at St Mary’s Hospital, London; the team was awarded the Best UK Clinical Team by Allergy UK in 2018. Paul’s research is funded by the Medical Research Council, FSA, European Commission, NIHR and EAT Foundation (USA). He is a visiting Honorary Consultant at a number Central London Hospitals, a paediatric consultant on allergy-related issues to Public Health England, and current Chair of the BSACI Paediatric Allergy Group and the WAO Anaphylaxis Committee. He is a member of the UK Food Standards Agency’s Science Council.

Allergopharma Award – Rodrigo Jimenez Saiz
Rodrigo Jiménez-Saiz is a Junior Group Leader at the Dept. of Immunology and Oncology at the National Center for Biotechnology (CNB-CSIC, Madrid, Spain) and a part-time Assistant Professor at the Dept. of Pathology and Molecular Medicine (McMaster University, Hamilton, Canada). He is also a part-time Teaching Professor of Biomedicine at the Universidad Francisco de Vitoria (Madrid, Spain) and a Visiting Researcher at the Spanish National Center for Cardiovascular Research (CNIC, Madrid, Spain). The Jiménez-Saiz Lab aims to understand immunological principles of Th2 immunity in the context of allergic disease, particularly as it pertains to acute allergic reactions (anaphylaxis) and its modulation by the microbiota, the maintenance of IgE immunity (memory responses), and the impact of allergic disease in the development of other pathologies. Rodrigo Jiménez-Saiz is an elected member of the Immunology Section of EAACI, Chair of a EAACI Task Force on public outreach and member of the Scientific Committee of FAAM 2020. He serves on a number of Editorial Boards including Allergy, International Archives of Allergy and Immunology, and Frontiers in Allergy, and was recently nominated Top Peer Reviewer in Immunology by Publons.
EAACI Activity Challenge

Overview
The Digital Congress delegates will be able to earn points at several check points and interactions along the way during the EAACI Digital Congress 2020 experience.

Available to all registered delegates during their visit to the virtual exhibition area when visiting, chatting, answering scientific questions, and providing valuable feedback to our industry partners.

Additionally, with the Leaderboard function, delegates will be able to see the live scores of the top 20 delegates.

EAACI would like to thank our Industry Sponsors for their support and dedication during these difficult times, this could not be done without the valuable contributions from them.

The digital information exchange at EAACI 2020 represents a new and exciting experience for us all. We encourage you to explore it all! Use your well-deserved breaks to network, inform and exchange.

How does it work?
- Once you have logged on to the EAACI 2020 Platform, the Activity challenge will appear on the Home Page.
  Click on the Activity Challenge icon which will prompt a description of the activities.
- Goal is to generate as many points as possible from the group of activities listed.
- Each activity will have a maximum amount of points that can be achieved, which will be distributed based on how much the attendee has completed.
  - As activities progresses, there are barriers that shows:
    - Activity completion status. Eg. You have completed 5/10 activities
    - Participants point total can be seen next to their profile.
  - In the case of multiple participants in the EAACI Activity Challenge tied with the most points on the overall points table, the winner will be automatically be identified based on the submission time of first completing the full Activity Challenge.

Company Sponsored Symposia
Industry Symposia will run in parallel with the main scientific programme on the digital programme. These symposia are organised independently by the sponsoring companies who also select the topics and speakers which are approved by the Scientific Programme Committee.

Digital Congress Poster Display (DCPD)
Digital Congress Poster Display (former On-Site Poster Display) can be found in the e-poster section of the Digital Congress. DCPD will not be published in the EAACI Media Library and the official journal of EAACI after the Congress.

Ethics Session (ES)
Ethics Session is a state of the art symposium in which the speakers critically review ethical aspects of topics related to Allergy and Clinical Immunology. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area. The Ethics Session will be available in the Recorded Scientific Programme only.

Hot Topics (HT)
Hot Topic Sessions consist of presentations. Topics are selected close to the time of the congress, with the goal of presenting new and exciting data in a more informal format than a typical session. Hot Topic Sessions allow members to gain insight into the latest news and findings in allergy and clinical immunology.

Interactive Symposia (ISYM) and Workshops (IWS)
Interactive Workshops are sessions in which speakers share and discuss evidence and experience gathered - clinical and/or basic - in a certain field. These sessions are interactive, and the speaker addresses some frequently asked questions with regards to the topic.

Interactive Postgraduate Courses (IPGC)
Interactive Postgraduate Courses are educational sessions where the speaker addresses some frequently asked questions with regards to the topic.

Keynote Symposia (KL)
Keynote Symposia are the core of the congress activities. These are exhaustive reviews of a major subject of the specialty, addressed to all congress participants. Plenary Symposia are scheduled at “prime times” in the programme, with no crossover with other activities to enable maximum attendance.

Late-Breaking Oral Abstract Sessions (LB OAS)
The most exciting work from late-breaking abstracts submitted to the congress will be honoured with a place in these sessions. Each presenter highlights their work.

Late-Breaking Poster Discussion Sessions (LB PDS)
LB PDS can be found in the e-poster section of the Digital Congress, together with a voice-over, and available in the EAACI Media Library.

Late-Breaking Thematic Poster Sessions (LB TPS)
LB TPS can be found in the e-poster section of the Digital Congress, together with a voice-over, and available in the EAACI Media Library.

Oral Abstract Sessions (OAS)
The most exciting work from abstracts submitted to the congress will be honoured with a place in these sessions. Each presenter highlights her/his work.

Poster Discussion Sessions (PDS)
PDS can be found in the e-poster section of the Digital Congress, together with a voice-over, and available in the EAACI Media Library.

Pro & Cons (P&C)
The Pro & Con Sessions allow speakers to debate controversial topics in an attractive format which provides “food for thought”. The Pro & Con Sessions will be available in the Recorded Scientific Programme only.

Sister Society Symposia (SSS)
EAACI has collaborated with a number of sister societies to develop symposia that represent regional or scientific areas common to EAACI and the sister society. This is a chance to expand your knowledge beyond the traditional boundaries. There will be 6 live SSS and the remaining ones will be available in the Recorded Scientific Programme only.
Symposia (SYM)
Symposia are state-of-the-art educational sessions in which the speakers critically review diverse aspects of a specific topic. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area. There will be 9 live SYM and the remaining ones will be available in the Recorded Scientific Programme only.

Thematic Poster Sessions (TPS)
TPS can be found in the e-poster section of the Digital Congress, together with a voice over, and available in the EAACI Media Library.

Year in Review (YIR)
The Year in Review Sessions are complete and authoritative, focused on the highlights published during the previous year on a specific topic.

Important Notice
Due to the change of format, we regret to inform you that the following sessions will not be part of the EAACI 2020 Digital Congress:
• Allied Health Day
• Business Meetings (BM)
• Company Sponsored Mini Symposia (CSMS)
• Clinical Village
• EAACI Immunology Course
• Learning Lounges (LL)
• Satellite Symposia (SAT)

Year in Review (YIR)
The Year in Review Sessions are complete and authoritative, focused on the highlights published during the previous year on a specific topic.

Description of Session Types

Programme at a Glance
This page gives an overview of the digital sessions organised on June 6, 2020. The original scientific programme created for the EAACI Congress 2020 in London includes much more content. It is possible to access this “Recorded Scientific Programme” by clicking on the link button on the right.
Saturday, 6 June 2020

**KS 1 The challenges of severe asthma**

Saturday, 6 June 2020 - 09:00-10:25 CET

**Learning objectives:**
- To discuss the role of microbiome in allergy and asthma.
- To discuss the role of exposome and asthma.
- To discuss the utility of machine learning and algorithms in asthma management.
- To discuss factors that influence asthma development from childhood to adulthood.

**Chairs**
Matteo Bonini (Italy), Liam O’Mahony (Ireland)

**The airway microbiome in asthma development - Q&A**
Benjamin Marsland (Australia)

**Exposomes and gene interaction in asthma - Q&A**
Kian Fan Chung (United Kingdom)

**The trajectory of lung disease from childhood to adulthood - Q&A**
Patrick Holt (Austria)

**Big data and cluster analysis: a real life perspective - Q&A**
Loana Octavia Agache (Romania)

**Launch of the Biological guidelines - Q&A**
Marek Jutel (Poland)
Oscar Palomares (Spain)

**SYM 01 Novel insights into the development of allergic disease**
Saturday, 6 June 2020 - 10:45-12:15 CET

**Learning objectives:**
- To discuss the properties of allergen and their role in allergy sensitization.
- To discuss novel insights into development of allergic diseases.
- To discuss the impact of multiple stressors through different environmental pathways and their impact on allergy.
- To discuss the impact of pollution on allergic diseases and outline call for actions.

**How do allergens sensitize?**
Barbara Bohle (Austria)

**Novel insight into development of allergic diseases**
Jean Bousquet (France)

**Epithelial cell barrier and allergic diseases**
Cezmi Akdis (Switzerland)

**Lifelong exposure to multiple stressors through different environmental pathways and their impact on allergy**
Isabella Annesi-Maesano (France)

**Air pollution and allergy: call for action!**
Stephen Holgate (United Kingdom)

**SYM 02 Food allergy: prevention is better than cure**
Saturday, 6 June 2020 - 12:45-14:15 CET

**Learning objectives:**
- To provide an update on current strategies of prevention of food allergy.
- To gain insight into issues that families have to implement these recommendations.
- To discuss therapeutic approaches to prevent food allergy derived from weaning products.
- To discuss the role of gut microbiota in development of food allergy and the use of symbiotics in the management of food allergy.
- To discuss the dietary and psychological issues observed in the allergy clinic related early to food introductions.

**Prevention of food allergy: where are we now?**
Gideon Lack (United Kingdom)

**Challenges on the implementation of early introduction of allergenic foods**
Edmond S. Chan (Canada)

**Over-the-counter allergy prevention weaning products**
Michael Perkin (United Kingdom)

**Latest developments in pre, pro and symbiotics in food allergy prevention**
Nikolaos Papadopoulos (Greece)

**Dietary and psychological issues related to food introductions**
Carina Venter (United States)

**SYM 03 Biologicals and other therapies in allergy: from clinical trials to clinical practice**
Saturday, 6 June 2020 - 14:45-16:15 CET

**Learning objectives:**
- To discuss and give evidence of anti-TSLP in severe uncontrolled asthma.
- To discuss and give evidence of anti-IL4Ra in atopic dermatitis.
- To discuss and give evidence of anti-IgE in chronic spontaneous urticaria.
- To discuss interferon therapy as an asthma preventative treatment approach.
- To discuss novel developments in biosimilars and drug development in Allergy.

**Tezepelumab (anti-TSLP) in asthma**
Jonathan Corren (United States)

**Dupilumab (anti-IL4Ra) in CRSwNP**
Claus Bachert (Belgium)

**Ligelizumab (anti-IgE) in chronic spontaneous urticaria**
Marcus Maurer (Germany)

**Interferon therapy and novel biologicals**
Sebastian Lennox Johnston (United Kingdom)

**Upcoming drug developments and biosimilars**
Matteo Bonini (Italy)

**Q&A**
Programme description

Saturday, 6 June 2020

SSS 01 EAACI - NIAID/NIH Joint Symposium: From bench to bedside: Potential therapeutics for allergic diseases from the NIAID-supported Asthma and Allergic Diseases Cooperative Research Centers Saturday, 6 June 2020 - 16:45-17:45 CET

Learning objectives:
• To discuss how to target Rhinovirus for asthma prevention.
• To discuss the utility of Glucagon-like-1 receptor agonist in asthma.
• To describe the therapeutic opportunities of Siglecs.

Targeting rhinovirus infection as a strategy for asthma prevention and treatment
James E Gern (United States)

Glucagon-like 1 receptor agonists: repurposing for asthma?
Ray Stokes Peebles, Jr. (United States)

Siglecs on eosinophils and mast cells: from biology to therapeutic opportunities
Bruce Scott Bochner (United States)

Q&A


Learning objectives:
• To discuss how to use the atopic Dermatitis Yardstick in the clinic.
• To discuss how to manage atopic dermatitis.
• To describe the novel therapeutic approaches in atopic dermatitis.

Using the “atopic dermatitis yardstick” in clinical practice
James L Sublett (United States)

Managing quality of life and comorbidity issues in atopic dermatitis
Michael S. Blaiss (United States)

JAK inhibitors and monoclonals: the future of atopic dermatitis management
Luz Fonacier (United States)

Q&A

Welcome Ceremony
Saturday, 6 June 2020 - 19:50-20:00 CET

OKS 1 The EAACI Congress 2020 opening Keynote Symposia: Solutions and challenges in modern medicine Saturday, 6 June 2020 - 20:00-21:00 CET

Learning objectives:
• To describe the journey of biologicals in modern medicine.
• To described and outline the impact of COVID-19 in health and respiratory airway disease.
• Immune modulation strategy in the management of COVID-19.

Chairs
Mohamed Shamji (United Kingdom), Marek Jutel (Poland)

Paving the way for biologicals in modern medicine (The Nobel Laureate Keynote Lecture)
Gregory Winter (United Kingdom)

Corona virus and lung inflammation - the current pandemic
Peter Openshaw (United Kingdom)

Immune modulation in the era of COVID19
Marek Jutel (Poland)

EAACI Awards
Saturday, 6 June 2020 - 21:00-21:15 CET

www.eaaci.org
SSS 03 EAACI - APAAACI joint symposium: Allergies in Asia Pacific: insights and lessons learnt east versus west
Sunday, 7 June 2020 - 09:00-10:20 CET

Learning objectives:
• To describe endotypes of upper airway disease and discuss the clinical effectiveness of novel biologics that target endotypes.
• To describe new emerging approaches in immunotherapy for inhalant allergens.
• To discuss the utility of artificial intelligence (machine learning) in biomarker discovery for immunotherapy.

Chairs
Cezmi Akdis (Switzerland), Stephen R Durham (United Kingdom)

Immunotherapy for food allergy: is tolerance too much of an expectation? - Q&A
George du Toit (United Kingdom)

Mechanisms of Oral, SLIT and other approaches of food immunotherapy - Q&A
Wayne G Shreffler (United States)

B cell tolerance: an essential mechanism for allergen immunotherapy in house dust mite allergy - Q&A
Mübeccel Akdis (Switzerland)

Artificial intelligence approach to understanding the mechanisms and biomarker discovery for allergen immunotherapy - Q&A
Mohamed Shamji (United Kingdom)
SYM 04 Utility of OMICs: a roadmap to precision medicine
Sunday, 7 June 2020 - 12:15-13:45 CET

Learning objectives:
• To discuss the novel computational models and current challenges.
• To discuss the OMICs data integration in allergy.
• To describe novel approaches to visualize and track tissue inflammation.
• To outline the advantages and disadvantages of untargeted and targeted metabolomics in phenotyping allergic diseases novel approaches to visualize and track tissue inflammation.
• The utility of system biology approaches to advance clinical patient care.

Human and computational models of immune mediated inflammatory skin disease: challenges, insights and perspectives
Nick Reynolds (United Kingdom)

Integrative OMICs data analysis reveals key drivers of peanut allergic reactions
Kari Christine Nadeau (United States)

Utility of single-cell RNA sequencing to identify distinct gene signature in airway Th2 cells
Jonathan Coquet (Sweden)

Utility of untargeted and targeted metabolomic approaches in phenotyping allergic diseases
Domingo Barber (Spain)

Integrated systems biology strategies for diagnostics and immune monitoring in allergy
Markus Ollert (Luxembourg)

Q&A

SSS 04 EAACI - ERS joint symposium: Asthma for the roaring 20-twenties
Sunday, 7 June 2020 - 14:15-15:15 CET

Learning Objectives:
• To provide an update on the big changes in asthma treatment: GINA 2019.
• To discuss the role of personalized medicine in severe asthma in low- and middle-income countries.
• To describe novel approaches to childhood asthma.

Big changes in asthma treatment: GINA 2019
Luis Pérez de Llano (Spain)

Tailored therapy in severe asthma: is it a dream in low- and middle-income countries?
Arzu Yorgancioglu (Turkey)

A system biology and machine learning approach to childhood asthma
Adnan Custovic (United Kingdom)

Q&A

SYM 05 Insights into the management of drug allergy
Sunday, 7 June 2020 - 15:45-17:15 CET

Learning objectives:
• To describe the differences in management of NSAID hypersensitivity in children and adults.
• To discuss the management of drug reactions in a perioperative setting.
• To describe the management of adverse reactions to biologics.

NSAID hypersensitivity of children vs adults
Marina Atanaskovic-Markovic (Serbia)

Drug reactions in the perioperative setting
Lene Heise Garvey (Denmark)

Early biomarkers for severe drug hypersensitivity reactions
Maria J Torres (Spain)

Management of adverse reactions to biologics
Mariana Castells (United States)

Utility of provocation tests before deciding to desensitize
Jean-Christoph Caubet (Switzerland)

Q&A

SYM 06 Novel mechanisms in united severe airway disease
Sunday, 7 June 2020 - 17:45-19:15 CET

Learning objectives:
• To describe the relationship between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.
• To describe novel insights in innate lymphoid cells in upper and lower airway disease and how they can be exploited for therapeutic use.
• To discuss the pathogenic and protective role of B cells in Chronic Rhinosinusitis.
• To discuss recent advances in genomics in severe airway disease.
• To describe and discuss the clinical effectiveness of novel biologics that target endotypes.

Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis
Atsushi Kato (United States)

Targeting innate lymphoid cells in lower and upper airway disease: what’s new?
Hideaki Morita (Japan)

B cells in chronic rhinosinusitis: friend or foe
Anja Tripathi Peters (United States)

Advances in genomics in severe airway disease
Sanna Toppila-Salmi (Finland)

Novel therapeutic approaches targeting endotypes of severe airway disease
Philippe Gevaert (Belgium)

Q&A

SYM 07 Insights into the management of drug allergy
Sunday, 7 June 2020 - 17:45-19:15 CET

Learning objectives:
• To describe the differences in management of NSAID hypersensitivity in children and adults.
• To discuss the management of drug reactions in a perioperative setting.
• To describe the management of adverse reactions to biologics.

NSAID hypersensitivity of children vs adults
Marina Atanaskovic-Markovic (Serbia)

Drug reactions in the perioperative setting
Lene Heise Garvey (Denmark)

Early biomarkers for severe drug hypersensitivity reactions
Maria J Torres (Spain)

Management of adverse reactions to biologics
Mariana Castells (United States)

Utility of provocation tests before deciding to desensitize
Jean-Christoph Caubet (Switzerland)

Q&A
Programme at a Glance

Sunday, 8 June 2020

This page gives an overview of the digital sessions organised on June 7, 2020. The original scientific programme created for the EAACI Congress 2020 in London includes much more content. It is possible to access this “Recorded Scientific Programme” by clicking on the link button on the right.

<table>
<thead>
<tr>
<th>CET Time</th>
<th>Track 1: Live Scientific Programme</th>
<th>Track 2: Industry Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>KS 3 - Keynote Symposium</td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td>Trained innate immunity and therapeutic target of immune-mediated disease</td>
<td></td>
</tr>
<tr>
<td>09:45</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Sym 7: Symposia</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Targeting the skin immune response for disease prevention and control</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Sym 8: Symposia</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>Targeting the microbiome for clinical care</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>Sym 9: Symposia</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Allergen immunotherapy: outcomes, mechanisms and biomarkers</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td>Sym 10: Symposia</td>
<td></td>
</tr>
<tr>
<td>12:45 - 14:15 CET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td>Sym 11: Symposia</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Sym 12: Symposia</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>Sym 13: Symposia</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Sym 14: Symposia</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Sym 15: Symposia</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>SSS 5: Sister Society Symposium</td>
<td></td>
</tr>
<tr>
<td>17:05 - 17:45 CET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>WAO joint symposium: World allergy forum: impact of climate change on allergic diseases</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Digital break</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>SSS 6: Sister Society Symposium</td>
<td></td>
</tr>
<tr>
<td>18:15 - 19:15 CET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>EAACI - AAAAI joint symposium: a new era in asthma management: perspectives from the United States</td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:15</td>
<td>19:15 - 19:30 CET Closing Ceremony</td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SYM 07 Targeting the skin immune response for disease prevention and control
Monday, 8 June 2020 - 10:45-12:15 CET
Learning objectives:
• To discuss the effect of the exposome in atopic dermatitis.
• To discuss the importance of biomarkers immunophenotyping of atopic dermatitis.
• To discuss how to target immune mechanisms and prevent asthma development.
• To describe and discuss the role of neutrophil dysfunction in immune deficiency.

Impact of the exposome in atopic dermatitis
Alan Irvine (Ireland)
Implementing biomarkers in immunophenotyping of atopic dermatitis
Edward Frank Knol (The Netherlands)
Skin care from birth for allergy prevention: results today
Helen A Brough (United Kingdom)
Novel targets for treatment in atopic dermatitis
Emma Guttman Yassky (United States)
Hereditary angioedema – the best way to prevent attacks
Clive Grattan (United Kingdom)

SYM 08 Targeting the microbiome for clinical care
Monday, 8 June 2020 - 12:45-14:15 CET
Learning objectives:
• To review how the microbiome modifies Immune Endotypes in Allergic Diseases.
• To describe the clinical applications of microbiome in allergy and cancer immunotherapy.
• To describe how antibiotics can alter the microbiome and modulate allergic inflammation in asthmatics the current knowledge on how microbiota modulate immune response and support immunotherapy.
• To describe the current knowledge on how microbiota modulate immune response and support immunotherapy.

Impact of the exposome in atopic dermatitis
Alan Irvine (Ireland)
Implementing biomarkers in immunophenotyping of atopic dermatitis
Edward Frank Knol (The Netherlands)
Skin care from birth for allergy prevention: results today
Helen A Brough (United Kingdom)
Novel targets for treatment in atopic dermatitis
Emma Guttman Yassky (United States)
Hereditary angioedema – the best way to prevent attacks
Clive Grattan (United Kingdom)

SYM 09 Allergen immunotherapy: outcome measures, mechanisms and biomarkers
Monday, 8 June 2020 - 14:45-16:15 CET
Learning objectives:
• To discuss the current approaches of allergen immunotherapy using in vivo allergen challenges.
• To describe the different approaches of monitoring clinical response following immunotherapy in adults and children.
• To describe the mechanisms and importance of T cell tolerance in allergen immunotherapy.
• To describe the relevance of B cell modulation in tolerance induction during immunotherapy.
• To describe immune monitoring biomarkers of immunotherapy.

Allergen immunotherapy: nasal allergen vs chamber challenges vs other tests
Stephen R Durham (United Kingdom)
Outcome measures for adult’s vs children in the clinic during allergen immunotherapy
Constantinos Pitsios (Cyprus)
T cell tolerance during allergen immunotherapy
Erik R Wambre (United States)
Benefit, risk ratio and improving oral allergen immunotherapy
Paul J Turner (United Kingdom)
Molecular immune biomarkers for protein-based and peptide immunotherapy
Mark Larché (Canada)
Programme description

Sunday, 8 June 2020

SSS 05 EAACI – WAO joint symposium: World allergy forum: impact of climate change on allergic diseases
Monday, 8 June 2020 - 16:45-17:45 CET

Learning objectives:
• To describe current understanding of how the environment is changing.
• To identify the effects on the immune system and allergic diseases such as allergic rhinitis and asthma.
• To evaluate environment-based and pharmacologic interventions.

Impact of climate change on the immune system
David B. Peden (United States)

International expert consensus on the management of allergic rhinitis aggravated by air pollutants
Philip Wakim Rouadi (Lebanon)

Impact of climate change on asthma exacerbations
Sandra Nora González Díaz (Mexico)

Q&A

SSS 06 EAACI - AAAAI joint symposium: A new era in asthma management: perspectives from the United States
Monday, 8 June 2020 - 18:15-19:15 CET

Learning Objectives:
• To demonstrate a personalized approach to the selection of a biologic agent for a patient with severe asthma.
• To discuss the current level of evidence on allergen abatement in asthma management.
• To describe differences in asthma guidelines.

Personalized asthma care - the use of biologics
Thomas Casale (United States)

Allergen abatement: the impact of environmental interventions in different patient populations
Wanda Phipatanakul (United States)

Reconciling differences in asthma guidelines
Leonard Bacharier (United States)

Q&A

Closing ceremony
Monday, 8 June 2020 - 19:15-19:30 CET

Presidential message & 2021 EAACI Congress announcement
### Speaker Index

This page gives an index of all the speakers of the Live Scientific Programme. The original scientific programme created for the EAACI Congress 2020 in London includes much more content and speakers. It is possible to access this "Recorded Scientific Programme" by clicking on the link button on the right.

#### Speaker Index

<table>
<thead>
<tr>
<th>Speaker name</th>
<th>Country</th>
<th>Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adnan Custovic</td>
<td>United Kingdom</td>
<td>June 7, SSS 4</td>
</tr>
<tr>
<td>Alan Irvine</td>
<td>Ireland</td>
<td>June 8, SYM 7</td>
</tr>
<tr>
<td>Alberto Mantovani</td>
<td>Italy</td>
<td>June 8, KS 3</td>
</tr>
<tr>
<td>Amir Hamzah Abdul Latiff</td>
<td>Malaysia</td>
<td>June 7, SSS 3</td>
</tr>
<tr>
<td>Anjoo Tripathi Peters</td>
<td>United States</td>
<td>June 7, SYM 6</td>
</tr>
<tr>
<td>Anne Marie Singh</td>
<td>United States</td>
<td>June 8, SYM B</td>
</tr>
<tr>
<td>Arzu Yorgancioglu</td>
<td>Turkey</td>
<td>June 7, SSS 4</td>
</tr>
<tr>
<td>Atsushi Kato</td>
<td>United States</td>
<td>June 7, SYM 6</td>
</tr>
<tr>
<td>Barbara Bohle</td>
<td>Austria</td>
<td>June 6, SYM 1</td>
</tr>
<tr>
<td>Benjamin Marsland</td>
<td>Australia</td>
<td>June 6, KS 1</td>
</tr>
<tr>
<td>Bruce Scott Bochner</td>
<td>United States</td>
<td>June 6, SSS 1</td>
</tr>
<tr>
<td>Carina Venter</td>
<td>United States</td>
<td>June 6, SYM 2</td>
</tr>
<tr>
<td>Cezi Akdis</td>
<td>Switzerland</td>
<td>June 6, SYM 1</td>
</tr>
<tr>
<td>Clare M Lloyd</td>
<td>United Kingdom</td>
<td>June 8, KS 3</td>
</tr>
<tr>
<td>Claus Bachert</td>
<td>Belgium</td>
<td>June 6, SYM 3</td>
</tr>
<tr>
<td>Clive Grattan</td>
<td>United Kingdom</td>
<td>June 8, SYM 7</td>
</tr>
<tr>
<td>Constantinos Pitsios</td>
<td>Cyprus</td>
<td>June 8, SSS 5</td>
</tr>
<tr>
<td>David B. Peden</td>
<td>United States</td>
<td>June 8, SSS 5</td>
</tr>
<tr>
<td>Domingo Barber</td>
<td>Spain</td>
<td>June 7, SYM 4</td>
</tr>
<tr>
<td>Edmond S. Chan</td>
<td>Canada</td>
<td>June 6, SYM 2</td>
</tr>
<tr>
<td>Edward Frank Knol</td>
<td>The Netherlands</td>
<td>June 8, SYM 7</td>
</tr>
<tr>
<td>Emma Gutman Yassky</td>
<td>United States</td>
<td>June 8, SYM 7</td>
</tr>
<tr>
<td>Erik R Wambre</td>
<td>United States</td>
<td>June 8, SYM 9</td>
</tr>
<tr>
<td>Eva Untersmyr</td>
<td>Austria</td>
<td>June 8, SYM 8</td>
</tr>
<tr>
<td>George du Toit</td>
<td>United Kingdom</td>
<td>June 7, KS 2</td>
</tr>
<tr>
<td>Gideon Lack</td>
<td>United Kingdom</td>
<td>June 6, SYM 2</td>
</tr>
<tr>
<td>Gregory Winter</td>
<td>United States</td>
<td>June 6, OKS 1</td>
</tr>
<tr>
<td>Helen A Brough</td>
<td>United Kingdom</td>
<td>June 8, SYM 7</td>
</tr>
<tr>
<td>Hideaki Morita</td>
<td>Japan</td>
<td>June 7, SYM 6</td>
</tr>
<tr>
<td>Ioana Octavia Agache</td>
<td>Romania</td>
<td>June 6, KS 1</td>
</tr>
<tr>
<td>Irene Heijrink</td>
<td>The Netherlands</td>
<td>June 8, KS 3</td>
</tr>
<tr>
<td>Isabella Arneri-Maesano</td>
<td>France</td>
<td>June 6, SYM 1</td>
</tr>
<tr>
<td>Isabelle Meyts</td>
<td>Belgium</td>
<td>June 8, SSS 3</td>
</tr>
<tr>
<td>James E Gern</td>
<td>United States</td>
<td>June 6, SSS 1</td>
</tr>
<tr>
<td>James L Sublett</td>
<td>United States</td>
<td>June 6, SSS 2</td>
</tr>
<tr>
<td>Jean Bousquet</td>
<td>France</td>
<td>June 6, SYM 1</td>
</tr>
<tr>
<td>Jean-Christoph Caubet</td>
<td>Switzerland</td>
<td>June 7, SYM 5</td>
</tr>
<tr>
<td>Ji-Yao Wang</td>
<td>Taiwan</td>
<td>June 7, SSS 3</td>
</tr>
<tr>
<td>Jonathan Coquet</td>
<td>Sweden</td>
<td>June 7, SYM 4</td>
</tr>
<tr>
<td>Jonathan Corren</td>
<td>United States</td>
<td>June 6, SYM 3</td>
</tr>
</tbody>
</table>

#### Recorded Scientific Programme

This page gives an index of all the speakers of the Live Scientific Programme. The original scientific programme created for the EAACI Congress 2020 in London includes much more content and speakers. It is possible to access this "Recorded Scientific Programme" by clicking on the link button on the right.

#### Speaker Index

<table>
<thead>
<tr>
<th>Speaker name</th>
<th>Country</th>
<th>Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kari Christine Nadeau</td>
<td>United States</td>
<td>June 7, SYM 4</td>
</tr>
<tr>
<td>Kian Fan Chung</td>
<td>United Kingdom</td>
<td>June 6, KS 1</td>
</tr>
<tr>
<td>Lene Heise Garvey</td>
<td>Denmark</td>
<td>June 7, SYM 5</td>
</tr>
<tr>
<td>Leonard Bacharier</td>
<td>United States</td>
<td>June 8, SSS 6</td>
</tr>
<tr>
<td>Liam O’Mahony</td>
<td>Ireland</td>
<td>June 8, SYM 8</td>
</tr>
<tr>
<td>Luis Pérez de Llano</td>
<td>Spain</td>
<td>June 7, SSS 4</td>
</tr>
<tr>
<td>Luz Fonacier</td>
<td>United States</td>
<td>June 6, SSS 2</td>
</tr>
<tr>
<td>Marcus Maurer</td>
<td>Germany</td>
<td>June 6, SYM 3</td>
</tr>
<tr>
<td>Marek Jutel</td>
<td>Poland</td>
<td>June 6, KS 1 &amp; OKS 1</td>
</tr>
<tr>
<td>Maria J Torres</td>
<td>Spain</td>
<td>June 7, SYM 5</td>
</tr>
<tr>
<td>Mariana Castells</td>
<td>United States</td>
<td>June 7, SYM 5</td>
</tr>
<tr>
<td>Marina Atanasovski-Markovic</td>
<td>Serbia</td>
<td>June 7, SYM 5</td>
</tr>
<tr>
<td>Mark Larché</td>
<td>Canada</td>
<td>June 8, SYM 9</td>
</tr>
<tr>
<td>Markus Ollert</td>
<td>Luxembourg</td>
<td>June 7, SYM 4</td>
</tr>
<tr>
<td>Matteo Bonini</td>
<td>Italy</td>
<td>June 6, SYM 3</td>
</tr>
<tr>
<td>Michael Perkin</td>
<td>United Kingdom</td>
<td>June 6, SYM 2</td>
</tr>
<tr>
<td>Michael S. Blais</td>
<td>United States</td>
<td>June 6, SSS 2</td>
</tr>
<tr>
<td>Mohamed Shamji</td>
<td>United Kingdom</td>
<td>June 7, KS 2</td>
</tr>
<tr>
<td>Mubeccel Akdis</td>
<td>Switzerland</td>
<td>June 7, KS 2</td>
</tr>
<tr>
<td>Nick Reynolds</td>
<td>United Kingdom</td>
<td>June 7, SYM 4</td>
</tr>
<tr>
<td>Nicosia Papadopoulos</td>
<td>Greece</td>
<td>June 6, SYM 2</td>
</tr>
<tr>
<td>Noorbalia Lunjani</td>
<td>Ireland</td>
<td>June 8, SSS 8</td>
</tr>
<tr>
<td>Oscar Pelomares</td>
<td>Spain</td>
<td>June 6, KS 1</td>
</tr>
<tr>
<td>Patrick Holt</td>
<td>Australia</td>
<td>June 6, KS 1</td>
</tr>
<tr>
<td>Paul J Turner</td>
<td>United Kingdom</td>
<td>June 8, SYM 9</td>
</tr>
<tr>
<td>Peter Oppenshaw</td>
<td>United Kingdom</td>
<td>June 6, OKS 1</td>
</tr>
<tr>
<td>Philip Wakim Rouadi</td>
<td>Lebanon</td>
<td>June 8, SSS 5</td>
</tr>
<tr>
<td>Philippe Gevaert</td>
<td>Belgium</td>
<td>June 7, SYM 6</td>
</tr>
<tr>
<td>Ray Stokes Peebles Jr.</td>
<td>United States</td>
<td>June 6, SSS 1</td>
</tr>
<tr>
<td>Ruby Pawankar</td>
<td>Japan</td>
<td>June 7, SSS 3</td>
</tr>
<tr>
<td>Sandra Nara González Díaz</td>
<td>Mexico</td>
<td>June 8, SSS 5</td>
</tr>
<tr>
<td>Sanna Toppila-Salmi</td>
<td>Finland</td>
<td>June 7, SYM 6</td>
</tr>
<tr>
<td>Sebastian Lennox Johnston</td>
<td>United Kingdom</td>
<td>June 6, SYM 3</td>
</tr>
<tr>
<td>Stephen Holgate</td>
<td>United Kingdom</td>
<td>June 6, SYM 1</td>
</tr>
<tr>
<td>Stephen R Durham</td>
<td>United Kingdom</td>
<td>June 8, SYM 9</td>
</tr>
<tr>
<td>Sylwia Smolinska</td>
<td>Poland</td>
<td>June 8, SYM 8</td>
</tr>
<tr>
<td>Thomas Casale</td>
<td>United States</td>
<td>June 8, SSS 6</td>
</tr>
<tr>
<td>Wanda Phistatpakul</td>
<td>United States</td>
<td>June 8, SSS 6</td>
</tr>
<tr>
<td>Wayne G Sheffler</td>
<td>United States</td>
<td>June 7, KS 2</td>
</tr>
</tbody>
</table>
The National Allergy Society Village is open throughout the entire Digital Congress and features the virtual booths of our NAS from all over Europe. At each booth you will be able to visualise brochures, watch videos, consult important national resources and much more. You will also have the chance to interact with respective members of the NAS through an e-mail form.

We encourage you to visit this area to learn more about your country’s very own society dedicated to allergy, asthma and immunology, or explore developments in the field from other countries.

<table>
<thead>
<tr>
<th>Country</th>
<th>Society Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>Association Belge de Formation Continue en Allergologie</td>
</tr>
<tr>
<td>Greece</td>
<td>Greek Pediatric Allergy Society</td>
</tr>
<tr>
<td>Greece</td>
<td>Hellenic Society of Allergology and Clinical Immunology</td>
</tr>
<tr>
<td>Italy</td>
<td>Italian Society of Allergology, Asthma and Clinical Immunology</td>
</tr>
<tr>
<td>Italy</td>
<td>Italian Association of Hospital and Territorial Allergists and Immunologists</td>
</tr>
<tr>
<td>Italy</td>
<td>Societatea Romane de Pneumologie</td>
</tr>
<tr>
<td>North Macedonia</td>
<td>Society of Pulmonologists of the Republic of Macedonia</td>
</tr>
<tr>
<td>Latin America</td>
<td>Sociedad Latino Americana de Allergia, Asma e Immunologia - Slaai</td>
</tr>
<tr>
<td>Poland</td>
<td>Polish Society of Allergology</td>
</tr>
<tr>
<td>Romania</td>
<td>Romanian Society of Pneumology</td>
</tr>
<tr>
<td>Serbia</td>
<td>Serbian Association for Allergology and Clinical Immunology</td>
</tr>
<tr>
<td>Turkey</td>
<td>Turkish Academy of Pediatric Allergy and Asthma</td>
</tr>
<tr>
<td>Turkey</td>
<td>Turkish National Society of Allergy and Clinical Immunology</td>
</tr>
<tr>
<td>Turkey</td>
<td>Turkish Society of Immunology</td>
</tr>
<tr>
<td>Turkey</td>
<td>Turkish Thoracic Society</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>The British Society for Allergy and Clinical Immunology - BSACI</td>
</tr>
<tr>
<td>Asia Pacific</td>
<td>Asia Pacific Academy of Pediatric Allergy, Respiratory and Immunology - APA</td>
</tr>
<tr>
<td>Asia Pacific</td>
<td>Asia Pacific Association of Allergy Asthma and Clinical Immunology - ACAAAI</td>
</tr>
</tbody>
</table>

**EAACI.org #eaaci2021**

**EAACI Congress 2021**

**European Academy of Allergy and Clinical Immunology**

**19-23 June 2021**

**MADRID**
Targeting IgE: what does it mean for patients, especially during this COVID-19 crisis?

We are pleased to invite you to this Novartis-sponsored virtual symposium, where leading clinicians will discuss perspectives and new findings on asthma, comorbidities and chronic spontaneous urticaria management. The panel will share their experience of how COVID-19 impacts their daily practice, and the consequences for management of patients with these IgE-mediated diseases. Targeting IgE, what does it mean for your patients, especially during the COVID-19 crisis?

Symposium will be streamed at
EAACI 2020 Congress on
Saturday 6 June 2020

Agenda
Chaired by Nikos Papadopoulos

- Welcome and Introduction
- What have we learned from the COVID-19 crisis?
- Perspectives and new findings on asthma and comorbidity management: what to EXPECT
- Omalizumab in chronic spontaneous urticaria, be AWARE
- Roundtable discussion
EAACI and the Local Organising Committee gratefully acknowledge the support of the 2020 Founder Sponsors.

Platinum Founder Sponsors EAACI Digital Congress 2020

Gold Founder Sponsor EAACI Digital Congress 2020

Silver Founder Sponsor EAACI Digital Congress 2020

Please click here to view the full list of the EAACI Founder Sponsors.

Dedicated to improving the lives of patients and families with food allergies

DBV is focused on discovering safe and effective treatments for patients with food allergies and other immunological diseases.
COMPANY SPONSORED SYMPOSIUM (CSS 1)
Sanofi Genzyme / Regeneron: Type 2 Inflammation in Atopic Dermatitis and Beyond: Shared Pathophysiology and Clinical Management
Saturday, 6 June 2020 - 10.30-11.45 CET
Welcome and Introduction
Marcus Maurer, Germany
Shared Pathophysiology and Epidemiology of Atopic Dermatitis with Other Type 2 Inflammatory Diseases
Marcus Maurer, Germany
Clinical Management of Atopic Dermatitis and Other Type 2 Inflammatory Diseases
Miriam Wittmann, United Kingdom
Panel Q&A
All faculty

COMPANY SPONSORED SYMPOSIUM (CSS 2)
MSD: Chronic Cough; What Allergists Need to Know
Saturday, 6 June 2020 - 12.00-13.15 CET
Chair: Joaquin Sastre, Spain
Welcome and Opening Remarks: Chronic cough and the allergist
Joaquin Sastre, Spain
What is the mechanism of chronic cough and the burden on patients and their subsequent journey through the Healthcare System?
Jaclyn Ann Smith, United Kingdom
What are the main causes of chronic cough and how to best diagnose and treat them?
Michael Blaiss, United States
Q&A via Chat
All faculty

COMPANY SPONSORED SYMPOSIUM (CSS 3)
Novartis Pharma AG: Targeting IgE: what does it mean for patients, especially during this COVID-19 crisis?
Saturday, 6 June 2020 - 13.30-14.45 CET
Chair: Nikolaos Papadopoulos, United Kingdom
Welcome and Introduction: What we have learned from the COVID-19 crisis?
Nikolaos Papadopoulos, United Kingdom
Perspectives and new findings on asthma and comorbidity management: what to EXPECT
Marc Humbert, France
Q&A
Nikolaos Papadopoulos, United Kingdom
Marc Humbert, France
Omalizumab in chronic spontaneous urticaria, be AWARE
Ana Maria Giménez-Arnau, Spain
Roundtable discussion
All faculty

COMPANY SPONSORED SYMPOSIUM (CSS 5)
Sanofi Genzyme / Regeneron: Dupilumab: Bridging Innovation in Biologic Treatment Across Type 2 Inflammatory Airway Diseases
Saturday, 6 June 2020 - 16.30-17.45 CET
Chair: William W. Busse, United States
Opening Remarks: Type 2 Inflammation in Airway Disease
William W. Busse, United States
Clinical Trial Evidence for Dupilumab in Patients With CRSwNP
Claus Bachert, Belgium
Patient Selection and Management Approaches in CRSwNP
Claus Bachert, Belgium
Dupilumab Clinical Insights in Type 2 Inflammatory Airway Diseases
Rafi Tachdjian, United States
Closing Remarks
William W. Busse, United States
**Company Sponsored Symposia**

**Sunday, 7 June 2020**

**COMPANY SPONSORED SYMPOSIUM (CSS 7)**  
Nestlé Health Science: New Advances in the Prevention and Management of Food Allergy  
Sunday, 7 June 2020 - 10:30-11.45 CET

Chair: Yvan Vandenplas, Belgium  
Nutritional Strategies for Food Allergy Prevention  
Carina Venter, United States  
Human Milk Oligosaccharides (HMO) for the Immune System Development  
Norbert Sprenger, Switzerland  
New data on the Benefits of HMO in the Management of Cow’s Milk Protein Allergy  
Anna Nowak-Wegrzyn, United States

**COMPANY SPONSORED SYMPOSIUM (CSS 8)**  
DBV TECHNOLOGIES: Life with Peanut allergy: What is the potential role of investigational Viaskin Peanut?  
Sunday, 7 June 2020 - 12.00-13.15 CET

Chairs:  
Helen Brough, United Kingdom  
Susanne Lau, Germany

Introduction  
Susanne Lau, Germany

The psycho-social impact of peanut allergy for children and their families  
Antonella Muraro, Italy

Can the increase in threshold of eliciting doses help peanut allergic subjects?  
Graham Roberts, United Kingdom

Investigational Viaskin Peanut clinical trial data: efficacy, safety, practicality  
Lars Lange, Germany

Conclusion  
Helen Brough, United Kingdom

**COMPANY SPONSORED SYMPOSIUM (CSS 9)**  
Sanofi Genzyme / Regeneron: Scoping CRSwNP: Putting the Spotlight on Type 2 Inflammation  
Sunday, 7 June 2020 - 13.30-14.00 CET

Chair: Peter Hellings, Belgium  
Evaluating CRSwNP Burden: A Closer Look at the Patient Experience  
Peter Hellings, Belgium

Type 2 Inflammation as the Key Driver of CRSwNP Pathophysiology  
Peter Hellings, Belgium

Treating CRSwNP: Evolving the Therapeutic Space With Biologics  
Claus Bachert, Belgium

**COMPANY SPONSORED SYMPOSIUM (CSS 10)**  
STALLERGENES GREER: Overcoming challenges in 2020: Bringing a positive outlook to allergic patients’ horizons  
Sunday, 7 June 2020 - 15.00-16.15 CET

Chair: Ludger Klimek, Germany  
COVID-19 Pandemic: AIT positioning in respiratory allergy  
Walter Canonica, Italy

Childhood AR and Asthma and development patterns of lung function  
Adnan Custovic, United Kingdom

Shaping the horizons of allergic patients  
Philippe Gevaert, Belgium

Expert panel discussion - Q&A Chat

**Transforming Allergy Lives**

Allergy Therapeutics

Experience our new look at the Virtual Exhibition of the EAACI Digital Congress 2020.

Join us to learn more on how Ultra-short Course Allergen Immunotherapy is transforming lives.
COMPANY SPONSORED SYMPOSIUM (CSS 11)
GSK: Mepolizumab: Targeting eosinophils in children and adults with severe eosinophilic asthma (SEA)
Sunday, 7 June 2020 - 16.30-17.45 CET
Chair: Neil Martin, United Kingdom
Welcome address from chair
Neil Martin, United Kingdom
An expert view of SEA in patients of all ages
Peter Gibson, Australia
Latest mepolizumab data: Long-term and real-world evidence in adults
Stephanie Korn, Germany
Building on the foundation of mepolizumab: Data in paediatric patients
Atul Gupta, United Kingdom
Expert opinion: Clinical cases in patients with SEA
Liam Heaney, United Kingdom
Peter Gibson, Australia
Stephanie Korn, Germany
Atul Gupta, United Kingdom
Neil Martin, United Kingdom
Closing remarks
Neil Martin, United Kingdom
Live chat Q&A
All faculty

COMPANY SPONSORED SYMPOSIUM (CSS 12)
Sanofi Genzyme / Regeneron: Type 2 Inflammation and Role of Key Mediators in the Clinical Hallmarks of Uncontrolled Severe Asthma
Sunday, 7 June 2020 - 18.00-19.15 CET
Chair: Leonard B. Bacharier, United States
Welcome and Opening Remarks
Leonard B. Bacharier, United States
Michael Wechsler, United States
Defining Control and Type 2 Inflammation in Severe Asthma
Michael Wechsler, United States
Elucidating the Roles Key Cytokines Play in Clinical Manifestations of Severe Asthma
Leonard B. Bacharier, United States
Applying Understanding of Type 2 Inflammation in Clinical Practice
All faculty
Closing / Q&A
All faculty

Sunday, 7 June 2020

OVERCOMING CHALLENGES IN 2020:
BRINGING A POSITIVE OUTLOOK TO ALLERGIC PATIENTS' HORIZONS

Introduction by Chair (5 minutes)
L. Klimek (Germany)

Presentations (20 minutes each)
COVID-19 Pandemic: AIT positioning in respiratory allergy
G.W. Canonica (Italy)
Childhood AR and asthma and development patterns of lung function
A. Custovic (United Kingdom)
Shaping the horizons of allergic patients
P. Gevaert (Belgium)
Q&A

YOU CAN ALSO VISIT OUR BOOTH IN THE DIGITAL EXHIBITION HALL, WHERE WE ARE FOCUSING ON SHAPING THE HORIZONS OF ALLERGIC PATIENTS.
COMPANY SPONSORED SYMPOSIUM (CSS 14)
Novartis Pharma AG: Breakthrough in the understanding of the anti-IgE pathway in CSU
Monday, 8 June 2020 - 12.00-13.15  CET

Chairs:
Marcus Maurer, Germany
Alexander Eggel, Switzerland

Introduction to CSU
Marcus Maurer, Germany

IgE inhibition in CSU: Not all anti-IgEs are born equal
Alexander Eggel, Switzerland

IgE inhibition implications: How does this benefit patients with CSU?
Marcus Maurer, Germany

Q&A
Marcus Maurer, Germany
Alexander Eggel, Switzerland

COMPANY SPONSORED SYMPOSIUM (CSS 17)
LETIPharma: AIT beyond pollens and mites. A future of opportunities.
Monday, 8 June 2020 - 18.00-19.15  CET

Chair: Ralph Mösges, Germany

Rare Alergens: Diagnostic and Treatment
Ludger Klimek, Germany

Clinical experience with depigmented polymerized cat immunotherapy
María Vázquez de la Torre, Spain

Immunotherapeutic alternatives for rare allergens
Jeronimo Carnés, Spain

Q&A
All faculty
## Exhibitor & Sponsor List

### Platinum Founder Sponsors 2020
- Allergy Therapeutics
- AstraZeneca PLC
- DBV Technologies
- Novartis Pharma AG
- Sanofi Genzyme / Regeneron
- Stallergenes Greer

### Gold Founder Sponsors 2020
- Allergopharma GmbH & Co. KG

### Silver Founder Sponsors 2020
- LETIPharma

### Exhibitors & Sponsors
- DST
- FAES FARMA
- GSK
- MacroArray Diagnostics
- MSD
- Nestlé Health Science
- Pharming Group N.V.
- Revenio Research / Ventica

### Societies
- American Academy of Allergy, Asthma and Immunology
- European Respiratory Society (ERS)

---

Visit the AstraZeneca digital exhibition booth to find out more.
Exhibitor & Sponsor Editorials

Allergopharma GmbH & Co. KG
Hermann-Körner-Straße 52
21465 Reinbek
Germany
+49 40 727650
www.allergopharma.com

Allergopharma is a German company that has been working successfully in allergy research, diagnostics and treatment for decades. We work alongside scientists and doctors to develop premium products for the allergy market which cover the entire treatment spectrum - from diagnostic tools to allergoids for allergen immunotherapy. With all our passion and expertise, we strive to find the best possible treatment for allergies to help people enjoy a fulfilled life. From 2013 to 2020 Allergopharma was fully integrated into Merck as the Allergy Business Unit. Since April 2020 Allergopharma is a company of the Dermapharm Holding.

Allergy Therapeutics
Dominion Way
BN14 8SA, Worthing
United Kingdom
+44 1903 844 700
www.allergytherapeutics.com

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease. We are a proud and passionate team of scientists and business specialists with a vision that delivers growth and transforms the way we think about immunology.

American Academy of Allergy, Asthma and Immunology
555 E. Wells St., Ste. 100
53202 Milwaukee
United States
+1 414 272 6071
www.aaaai.org

The American Academy of Allergy, Asthma & Immunology (AAAAI) is a professional organization with more than 7,000 members in the United States, Canada and 72 other countries. This membership includes allergist / immunologists, other medical specialists, allied health and related healthcare professionals - all with a special interest in the research and treatment of allergic and immunologic diseases.

AstraZeneca PLC
1 Francis Crick Ave
CB2 0RE, Cambridge
United Kingdom
+44 20 3749 5000
www.astrazeneca.com

Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019. Building on a 50-year heritage, the Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company’s early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell repair processes in disease and neuronal dysfunction.
DBV TECHNOLOGIES
Avenue Pierre Brossolette 177-181
92120, Montrouge
France
+33 1 55 42 78 78
www.dbv-technologies.com

DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy. We are committed to developing safe and effective therapies for food allergic patients. DBV is currently developing epicutaneous immunotherapy, or EPIT, which delivers biologically active compounds to the immune system through intact skin.

DST
Güterbahnhofstr. 16
19059, Schwerin
Germany
+49 385303480
www.dst-diagnostic.com

DST GmbH develops, manufactures and markets in-vitro diagnostics. The product portfolio includes different test systems for laboratory use as well as for point-of-care. Over 600 high quality allergens, produced and characterized in-house, form the basis for professional allergy diagnostics. Semi- and fully automatic test systems enable laboratories to detect human antibodies in serum or plasma samples by use of allergen-coated microtiter plates or strips. Point-of-care tests allow medical professionals to test their patients immediately and reliably with just a few drops of capillary blood.

New Advances in the Prevention and Management of Food Allergy

Sunday 7th June 2020 | 10:30 am – 11:45 am (CET)
Chairperson: Prof. Yvan Vandenplas | Belgium

How to Implement Nutritional Strategies for Food Allergy Prevention?

Dr. Carina Venter
Section of Allergy and Immunology
Children’s Hospital Colorado
University of Colorado
Denver, CO, USA

Human Milk Oligosaccharides (HMO) for the Immune System Development

Dr. Norbert Sprenger
Nestlé Research
Vers-chez-les-Blanc, Lausanne
Switzerland

New Data on the Benefits of HMO in the Management of Cow’s Milk Protein Allergy

Prof. Anna Nowak-Wegrzyn
Allergy and Immunology Department of Pediatrics
Hasan Findik Children’s Hospital
1010 Langone Health
New York, NY, USA

June 8th at 18:00 CET

AIT BEYOND POLLENS AND MITES. A FUTURE OF OPPORTUNITIES.

Chairman: Prof. Dr. Ralph Mösges, Germany
Rare allergens: diagnostic and treatment
Prof. Dr. Ludger Klimek, Germany
Clinical experience with depigmented polymerized cat immunotherapy
Dra. María Vázquez de la Torre, Spain
Immunotherapeutic alternatives for rare allergens
Dr. Jerónimo Carnés, Spain
For over 50 years, GSK has led the way in the management and treatment of respiratory disease with the aim of helping people do more, feel better and live longer. At EAACI Digital Congress 2020, we will share the latest clinical evidence to advance the treatment of severe eosinophilic asthma (SEA), as we believe that every person with an eosinophilic driven disease should be able to live a fulfilling life. We invite you to join us at our satellite symposium on Sunday June 7th at 16.30 – 17.45 at CSS 11 and to learn more by visiting our virtual exhibition stand.

Exhibitor & Sponsor Editorials

**European Respiratory Society (ERS)**
Avenue Ste Luce 4
1003, Lausanne, Switzerland
+41 21 213 01 01
[www.ersnet.org](http://www.ersnet.org)

The European Respiratory Society (ERS) is an international organisation that brings together physicians, healthcare professionals, scientists and other experts working in respiratory medicine. It is one of the leading medical organisations in the respiratory field, with a growing membership representing over 170 countries worldwide. Its mission is to promote lung health in order to alleviate suffering from disease and drive standards for respiratory medicine globally.

**LETI Pharma**
Gran Via de Les Corts Catalanes 184 – 7ª planta
08038, Barcelona, Spain
+34 933940536
[www.leti.com](http://www.leti.com)

LETI Pharma is an independent and family-owned biopharmaceutical research company. In its different areas of expertise, it seeks to contribute products to society that add value to health care. Its headquarters are in Barcelona and its industrial plant and allergy research laboratory are in Tres Cantos (Madrid). It has subsidiaries in Germany (Ismaning and Witten) and Portugal (Oporto). LETI Pharma operates with exclusive distributors in several countries in Europe, Latin America and Africa.

**MacroArray Diagnostics**
Lemböckgasse 59/Top 4
1230, Vienna, Austria
+43 8652573
[www.macroarraydx.com](http://www.macroarraydx.com)

MacroArray Diagnostics is a Vienna-based MedTech company. We develop, produce, and distribute tests, instruments and software for allergy diagnostics and research applications. Our products allow flexible, reliable, and affordable sensitisation profiling of each patient. Our multidisciplinary team ensures that customers receive the most advanced tools to fulfill their diagnostic needs.

**GSK**
Great West Road 980
TW8 9GS, Brentford, Middlesex, United Kingdom
+44 2080475000
[www.gsk.com](http://www.gsk.com)

For over 50 years, GSK has led the way in the management and treatment of respiratory disease with the aim of helping people do more, feel better and live longer. At EAACI Digital Congress 2020, we will share the latest clinical evidence to advance the treatment of severe eosinophilic asthma (SEA), as we believe that every person with an eosinophilic driven disease should be able to live a fulfilling life. We invite you to join us at our satellite symposium on Sunday June 7th at 16:30 – 17:45 at CSS 11 and to learn more by visiting our virtual exhibition stand.

(March 2020; PM-GBL-MPL-WCNT-200002)
For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. For more information, visit our website and connect with us on Twitter, LinkedIn and YouTube.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.

Pharming is a specialty pharmaceutical company based in the Netherlands, developing innovative products for the treatment of rare diseases and unmet medical needs. We use transgenic technology to develop pioneering treatments, focusing on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Founded in 1988, Pharming has experienced rapid growth recently, but our greatest asset remains our people. With a global workforce of more than 200 highly skilled people, we are committed to transforming the future for our patients.

Revenio Research is part of Revenio Group Corporation, a Finnish health tech group listed on Nasdaq Helsinki. Our lung function test provides valuable information to support clinical decision-making in young children (5 years and younger) with recurrent wheeze and/or asthma. The test provides an easy-to-interpret, objective result after a nocturnal measurement at home. Today Revenio Group is well-known for tonometers used in ophthalmology. Our vision is to become the provider of choice for unique healthcare solutions.